Shelygin M. Clinical and pathogenetic substantiation of using a2B interferon in treatment of patients with leiomyoma uteri.

The thesis covers the problems of optimizing conservative therapy of patients with leiomyoma uteri by scientific substantiation of using a2B interferon and evaluating its clinical effectiveness on the grounds of investigation of some clinical cytokine mecha-nisms of leiomyoma pathogenesis. In this connection 168 patients with different leio-myoma types and 30 healthy women were examined. 33,9% patients were diagnosed iso-lated leiomyoma, 66,1% - leiomyoma in combination with endo- and myometrium hyper-plasia. There was shown the correlation of variants of leiomyoma clinical course with pro-duction of TNF-B, IL-8, IL-4, B-interferon in systemic and regional blood flow. In case of the combination of leiomyoma with endometrium hyperplasia and adenomyosis the level of TNF-B and ?-interferon is reduced in blood by a factor of 2,8 and 8,1. The ?-interferon level in blood serum of less than 30 picograms per ml. is a diagnostic criterion of the com-bination of leiomyoma with endometrium hyperplasia and adenomyosis. It was proved that TNF-B, IL-8, IL-4 concentration was rising sharply. The highest levels of TNF-B, IL-8, IL-4 were discovered in cases of intramural nods localization. Scientifically proved B-interferon therapy of patients with leiomyoma uteri allowed to decrease TNF-B Blevel in blood by a factor 6, reduce the symptoms severity by a factor 3,3, achieve clinical and pathogenetic effectiveness in 90,4% cases.